Figure 1. Patients with Noncastrate Recurrent, Advanced, or
Metastatic Prostate Cancer
Biochemical
recurrence
after RP and/or
RT only*
Locally
advanced
Unwilling or
unable to
undergo RT
Early ADT
Active
surveillance
Low risk
Undergoing
RT
ADT +
abiraterone +
predisnone/
prednisolone
Intermittent
ADT
High risk
* Consult Lowrance WT et al, 2020
1
(American Urological Association/American Society
for Radiation Oncolog y/Society of Urologic Oncolog y Advanced Prostate Cancer: AUA/
ASTRO/SUO Guideline PART I) and Bekelman JE, 2018
2
(ASCO clinical practice guideline
endorsement of an American Urological Association/American Society for Radiation Oncolog y/
Society of Urologic Oncolog y guideline) for further information regarding salvage therapy
options aer failure of local therapy.
1
Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS,
Morgan TM, Morgans AK, Oh WK. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline
PART I. e Journal of Urolog y. doi:10.1097/JU.0000000000001375
